{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T17:10:01Z","timestamp":1776013801402,"version":"3.50.1"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2016,10,3]],"date-time":"2016-10-03T00:00:00Z","timestamp":1475452800000},"content-version":"vor","delay-in-days":608,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>SMT19969 is a novel narrow-spectrum antimicrobial under development for the treatment of Clostridium difficile infection (CDI). The objectives were to assess the relative efficacies of SMT19969, vancomycin and fidaxomicin in the hamster model of CDI.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Hamsters were infected with either C. difficile BI1 (ribotype 027) or C. difficile 630 (ribotype 012) prior to treatment with vehicle, SMT19969, fidaxomicin or vancomycin for 5 days. Animals were further monitored through to day 28 and survival recorded. Plasma and gastrointestinal concentrations of SMT19969 following single and repeat administration in infected hamsters were determined.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Following infection with C. difficile BI1, treatment with SMT19969, vancomycin and fidaxomicin resulted in 100% survival during the 5 day dosing period, with 90%\u2013100% of animals receiving SMT19969 and fidaxomicin surviving during the post-dosing follow-up period. Whilst protective during treatment, onset of mortality was observed on day 11 in animals treated with vancomycin, with a 10% survival recorded by day 28. Similar results were observed for SMT19969 and vancomycin following infection with C. difficile 630, with day 28 survival rates of 80%\u2013100% and 0%, respectively. Fidaxomicin protected animals infected with C. difficile 630 from mortality during dosing, although day 28 survival rates varied from 0% to 40% depending on dose. Plasma levels of SMT19969 were typically below the limit of quantification, but levels in the gastrointestinal tract remained far in excess of the MIC.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>These data show that SMT19969 is highly effective at treating both acute infection and preventing recurrent disease and support continued investigation of SMT19969 as a potential therapy for CDI.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkv005","type":"journal-article","created":{"date-parts":[[2015,2,5]],"date-time":"2015-02-05T01:59:33Z","timestamp":1423101573000},"page":"1757-1762","source":"Crossref","is-referenced-by-count":34,"title":["SMT19969 for <i>Clostridium difficile<\/i> infection (CDI): <i>in vivo<\/i> efficacy compared with fidaxomicin and vancomycin in the hamster model of CDI"],"prefix":"10.1093","volume":"70","author":[{"given":"Abdul","family":"Sattar","sequence":"first","affiliation":[{"name":"1 \u00a0Evotec (UK), Williams House, Manchester Science Park, Lloyd Street North, Manchester M15 6SE, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pia","family":"Thommes","sequence":"additional","affiliation":[{"name":"1 \u00a0Evotec (UK), Williams House, Manchester Science Park, Lloyd Street North, Manchester M15 6SE, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lloyd","family":"Payne","sequence":"additional","affiliation":[{"name":"1 \u00a0Evotec (UK), Williams House, Manchester Science Park, Lloyd Street North, Manchester M15 6SE, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Warn","sequence":"additional","affiliation":[{"name":"1 \u00a0Evotec (UK), Williams House, Manchester Science Park, Lloyd Street North, Manchester M15 6SE, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard J.","family":"Vickers","sequence":"additional","affiliation":[{"name":"2 \u00a0Summit plc, Abingdon, Oxfordshire, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2015,2,3]]},"reference":[{"key":"2022020123413107400_DKV005C1","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1093\/cid\/cis430","article-title":"Decreased cure and increased recurrence rates for Clostridium difficile infection caused by the epidemic C. difficile BI strain","volume":"55","author":"Petrella","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2022020123413107400_DKV005C2","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/ng.2478","article-title":"Emergence and global spread of epidemic healthcare-associated Clostridium difficile","volume":"45","author":"He","year":"2013","journal-title":"Nat Genet"},{"key":"2022020123413107400_DKV005C3","doi-asserted-by":"crossref","first-page":"4214","DOI":"10.1128\/AAC.02775-13","article-title":"Strain types and antimicrobial resistance patterns of Clostridium difficile isolates from the United States, 2011 to 2013","volume":"58","author":"Tickler","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2022020123413107400_DKV005C4","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S1473-3099(14)70991-0","article-title":"Underdiagnosis of Clostridium difficile across Europe: the European, multicentre, prospective, biannual, point-prevalence study of Clostridium difficile infection in hospitalised patients with diarrhoea (EUCLID)","volume":"14","author":"Davies","year":"2014","journal-title":"Lancet Infect Dis"},{"issue":"Suppl 6","key":"2022020123413107400_DKV005C5","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/1469-0691.12046","article-title":"Can we identify patients at high risk of recurrent Clostridium difficile infection?","volume":"18","author":"Kelly","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"2022020123413107400_DKV005C6","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S1473-3099(11)70374-7","article-title":"Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial","volume":"12","author":"Cornely","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"2022020123413107400_DKV005C7","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa0910812","article-title":"Fidaxomicin versus vancomycin for Clostridium difficile infection","volume":"364","author":"Louie","year":"2011","journal-title":"N Engl J Med"},{"key":"2022020123413107400_DKV005C8","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1177\/1756283X13508519","article-title":"Clostridium difficile infection: management strategies for a difficult disease","volume":"7","author":"Khanna","year":"2014","journal-title":"Therap Adv Gastroenterol"},{"key":"2022020123413107400_DKV005C9","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/cid\/ciu313","article-title":"Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials","volume":"59","author":"Johnson","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2022020123413107400_DKV005C10","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1128\/AAC.02184-13","article-title":"Comparative in vitro activities of SMT19969, a new antimicrobial agent, against 162 strains from 35 less frequently recovered intestinal Clostridium species: implications for Clostridium difficile recurrence","volume":"58","author":"Goldstein","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2022020123413107400_DKV005C11","doi-asserted-by":"crossref","first-page":"4872","DOI":"10.1128\/AAC.01136-13","article-title":"Comparative in vitro activities of SMT19969, a new antimicrobial agent, against Clostridium difficile and 350 Gram-positive and Gram-negative aerobic and anaerobic intestinal flora isolates","volume":"57","author":"Goldstein","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2022020123413107400_DKV005C12","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/978-1-60327-365-7_14","article-title":"Refinement of the hamster model of Clostridium difficile disease","volume":"646","author":"Douce","year":"2010","journal-title":"Methods Mol Biol"},{"key":"2022020123413107400_DKV005C13","doi-asserted-by":"crossref","first-page":"5714","DOI":"10.1128\/AAC.02903-14","article-title":"In vivo assessment of SMT19969 in a hamster model of Clostridium difficile infection","volume":"58","author":"Weiss","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2022020123413107400_DKV005C14","article-title":"Efficacy comparison between LFF571 and fidaxomicin in the hamster model of Clostridium difficile infection","author":"McKenney"},{"key":"2022020123413107400_DKV005C15","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1128\/AAC.35.6.1108","article-title":"In vitro and in vivo evaluation of tiacumicins B and C against Clostridium difficile","volume":"35","author":"Swanson","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"key":"2022020123413107400_DKV005C16","doi-asserted-by":"crossref","first-page":"145","DOI":"10.4161\/gmic.19526","article-title":"Models for the study of Clostridium difficile infection","volume":"3","author":"Best","year":"2012","journal-title":"Gut Microbes"},{"key":"2022020123413107400_DKV005C17","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1099\/00222615-24-1-53","article-title":"Clostridium difficile\u2014a spectrum of virulence and analysis of putative virulence determinants in the hamster model of antibiotic-associated colitis","volume":"24","author":"Borriello","year":"1987","journal-title":"J Med Microbiol"},{"key":"2022020123413107400_DKV005C18","doi-asserted-by":"crossref","first-page":"e46966","DOI":"10.1371\/journal.pone.0046966","article-title":"Succession in the gut microbiome following antibiotic and antibody therapies for Clostridium difficile","volume":"7","author":"Peterfreund","year":"2012","journal-title":"PLoS One"},{"key":"2022020123413107400_DKV005C19","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1093\/infdis\/jit426","article-title":"Importance of toxin A, toxin B, and CDT in virulence of an epidemic Clostridium difficile strain","volume":"209","author":"Kuehne","year":"2014","journal-title":"J Infect Dis"},{"issue":"Suppl 2","key":"2022020123413107400_DKV005C20","doi-asserted-by":"crossref","first-page":"S162","DOI":"10.1093\/cid\/cis453","article-title":"Fidaxomicin inhibits spore production in Clostridium difficile","volume":"55","author":"Babakhani","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2022020123413107400_DKV005C21","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1128\/IAI.00147-12","article-title":"The Clostridium difficile spo0A gene is a persistence and transmission factor","volume":"80","author":"Deakin","year":"2012","journal-title":"Infect Immun"},{"key":"2022020123413107400_DKV005C22","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1128\/IAI.00558-09","article-title":"Antibiotic treatment of Clostridium difficile carrier mice triggers a supershedder state, spore-mediated transmission, and severe disease in immunocompromised hosts","volume":"77","author":"Lawley","year":"2009","journal-title":"Infect Immun"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/70\/6\/1757\/42358596\/jac_70_6_1757.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/70\/6\/1757\/42358596\/jac_70_6_1757.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T23:43:41Z","timestamp":1643759021000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/70\/6\/1757\/728214"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,3]]},"references-count":22,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2015,2,3]]},"published-print":{"date-parts":[[2015,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkv005","relation":{},"ISSN":["1460-2091","0305-7453"],"issn-type":[{"value":"1460-2091","type":"electronic"},{"value":"0305-7453","type":"print"}],"subject":[],"published-other":{"date-parts":[[2015,6]]},"published":{"date-parts":[[2015,2,3]]}}}